Genentech Raises Tarceva Price
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm says 8% hike will support further R&D, not impact patient access.
You may also be interested in...
Genentech Adds Patient Assistance Program Along With Avastin Lung Cancer Indication
Program similar to Amgen’s for Vectibix.
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Exec discusses the firm’s pulmonary arterial hypertension drug Tracleer and other endothelin receptor antagonists in Actelion’s pipeline.